Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.02B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  DOMH
Dominari Holdings
DOMH
40 / 100
Penny Stock
$2.71arrow_drop_down1.81%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$2.71
Prev. Close$2.76
EPS-4.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap16380379.00
PE Ratio-
LOWHIGH
Day Range2.70
2.83
52 Week Range1.76
3.69
Ratios
P/B Ratio0.32
Revenue$2.03M
Operating M. %-551.94%
Earnings$0.00
Earnings Growth %-3.51%
EBITDA Margin %-1,000.00%
ROE %-36.12%
EPS-4.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

40vs 56. Market Avg.

All Score 40 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

DOMHMARKET
Value5340
Quality2540
Ownership1617
Growth3445
Dividends-38
check_circle

Dominari Holdings's Price discount from all time high of 100% is great compared to market average of 42.05%. This indicates DOMH could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$742.66
24H (%)arrow_drop_down0.40%
24H ($)-$3.03
MARKET CAP$695.32B
PRICE$482.47
24H (%)arrow_drop_down0.76%
24H ($)-$3.70
MARKET CAP$452.88B
PRICE$147.28
24H (%)arrow_drop_down1.52%
24H ($)-$2.28
MARKET CAP$359.34B
PRICE$125.62
24H (%)arrow_drop_down0.99%
24H ($)-$1.25
MARKET CAP$321.54B

About Dominari Holdings (DOMH)

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Anthony C. Hayes Esq.
Headquarters
New York
Employees
7
Exchange
NASDAQ
add Dominari Holdings to watchlist

Keep an eye on Dominari Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Dominari Holdings's (DOMH) price per share?

The current price per share for Dominari Holdings (DOMH) is $2.71. The stock has seen a price change of -$0.05 recently, indicating a -1.81% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Dominari Holdings (DOMH)?

For Dominari Holdings (DOMH), the 52-week high is $3.69, which is 36.16% from the current price. The 52-week low is $1.76, the current price is 53.98% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Dominari Holdings (DOMH) a growth stock?

Dominari Holdings (DOMH) has shown an average price growth of -41.57% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Dominari Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Dominari Holdings (DOMH) stock price performance year to date (YTD)?

As of the latest data, Dominari Holdings (DOMH) has a year-to-date price change of 2.26%. Over the past month, the stock has experienced a price change of 24.88%. Over the last three months, the change has been 30.92%. Over the past six months, the figure is 40.41%. Looking at a longer horizon, the five-year price change stands at -94.79%.

help
Is Dominari Holdings (DOMH) a profitable company?

Dominari Holdings (DOMH) has a net income of -$22.88M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 78.32% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -551.94% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.04M, although specific revenue growth data is currently not available. The gross profit is $1.6M. Operating income is noted at -$21.8M. Furthermore, the EBITDA is -$21.41M.

help
What is the market capitalization of Dominari Holdings (DOMH)?

Dominari Holdings (DOMH) has a market capitalization of $16.38M. The average daily trading volume is 10.35K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.